P21 is a Cerebrolysin-derived peptide described as a preclinical neurogenesis research compound. The supplied literature set does not establish patient dosing, clinical benefits, or safety for P21 itself. This page separates P21-specific facts from unrelated peptide studies and explains why clinician guidance matters.
Wondering if peptide therapy is right for you? Take the 3-min clinical quiz.
See if you qualify →What it is
P21 is described in the supplied materials as a Cerebrolysin-derived peptide. A peptide is a short chain of amino acids, the building blocks of proteins.
Names matter here. The supplied materials give no brand name, no generic INN, and no Chia compounded variant for P21. The most accurate plain-language description is: P21, a Cerebrolysin-derived peptide in the broader peptide class, discussed online for preclinical neurogenesis research.
P21 should not be confused with other peptide topics. For example, Semax, CJC-1295, and Ipamorelin are separate compounds with separate evidence questions. Evidence for one peptide does not automatically apply to another.
Names, class, and how to describe it accurately
| Identifier | What the supplied materials support | What not to assume |
|---|---|---|
| Name | P21 | Do not assume a brand name from the supplied evidence. |
| Source description | Cerebrolysin-derived peptide | Do not assume it has the same effects as Cerebrolysin. |
| Class | Peptide | Do not treat all peptide studies as P21 studies. |
| Common online topic | Neurogenesis and preclinical research | Do not infer human cognitive, longevity, or neurologic benefit from unrelated trials. |
| Chia offering | Not listed in Chia’s live treatment catalog | Do not assume Chia offers, prescribes, compounds, or ships P21. |
Mechanism of action
The mechanism of P21 in humans is unestablished in the supplied evidence set. Neurogenesis claims should be described as proposed or preclinical unless they are tied to P21-specific human data.
This distinction is important because the retrieved randomized trials involve other agents. Oral icotrokinra and another oral interleukin-23-receptor antagonist peptide were studied for plaque psoriasis, not P21 neurogenesis or cognition 1 2.
Collagen peptide trials can only support narrow statements about the collagen products and skin outcomes studied in those trials 3 4. They cannot be used to claim that P21 changes brain function, aging, or longevity.
The same rule applies to GLP-1-related research. Trials of exenatide, lixisenatide, mazdutide, survodutide, dulaglutide, semaglutide, and orforglipron concern those agents and their studied conditions, not P21 5 6 7 8 9 10.
Neurogenesis claims and the limits of preclinical evidence
Neurogenesis means the formation of new nerve cells. It is a real biology term, but it is often used too loosely online. For P21, the supplied evidence set does not provide P21-specific human randomized trial results showing improved neurogenesis, memory, cognition, or daily function.
At Chia, we treat evidence-limited peptide questions with caution. We separate mechanism ideas from human outcomes, and we avoid turning preclinical or unrelated data into patient promises.
Why unrelated peptide studies cannot be used as P21 evidence
A trial can be high quality and still not answer the P21 question. For example, randomized trials in plaque psoriasis can help describe the studied dermatology drug, its population, and its endpoints, but they do not establish P21 effects 1 2.
That is why this page does not borrow findings from unrelated compounds. If you are also reading about aging biology, our guides to cellular senescence and cellular senescence and aging explain how to keep lab findings separate from human outcomes.
Evidence
Evidence grade: A. The assigned grade is based on the quantity and design of published evidence captured by the grading system, not proof that P21 works or is safe.
A — two or more human randomised controlled trials. B — one human randomised trial, or two or more human clinical trials. C — human research exists, none of it randomised. D — animal or in-vitro research only; no human studies indexed. E — no trial evidence indexed in PubMed. The grade describes the quantity and design of published evidence, not whether the substance works, and not whether it is safe.
For this P21 page, the honest reading is that the supplied literature pool includes many randomized trials, but the listed trials are not P21-specific efficacy trials. Several are peptide or peptide-like drug studies in psoriasis, collagen supplement studies in skin outcomes, or GLP-1-related trials in metabolic, neurologic, or pressure-related conditions 1 2 3 4 5 6 7 8 9 10.
Why the grade does not prove P21 works or is safe
Evidence grades can be misunderstood. A high grade can reflect many human randomized trials in a broad search set, while still leaving the key patient question unanswered: did this exact compound help people in well-run human studies?
In the retrieved evidence set, P21-specific patient benefits, dosing, and long-term safety are not established. That means claims about cognition, neuroprotection, anti-aging, or longevity should not be presented as proven human effects.
What the supplied human trials can and cannot tell us
| Study type in supplied set | Examples | What it can support | What it cannot support |
|---|---|---|---|
| Dermatology peptide or peptide-like trials | Icotrokinra and an IL-23 receptor antagonist peptide for plaque psoriasis | Statements about those studied psoriasis agents and their trial context 1 2 | P21 effects on neurogenesis, cognition, or aging |
| Collagen peptide trials | Low-molecular-weight collagen peptide studies in healthy adults | Narrow statements about the tested collagen products and skin outcomes 3 4 | P21 effects on brain, memory, or longevity |
| GLP-1-related trials | Exenatide, lixisenatide, mazdutide, survodutide, dulaglutide, semaglutide, or orforglipron studies | Statements about those specific metabolic or neurologic research settings 5 6 7 8 9 10 | P21 dosing, safety, or efficacy |
What studies exist
| Year | Design | Study | Journal | Record |
|---|---|---|---|---|
| 2025 | Randomised controlled trial | Oral Icotrokinra for Plaque Psoriasis in Adults and Adolescents | The New England journal of medicine | PMID 41191940 |
| 2024 | Randomised controlled trial | A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings | Nature metabolism | PMID 38316982 |
| 2024 | Randomised controlled trial | Effect of glucagon like peptide-1 receptor agonist exenatide, used as an intracranial pressure lowering agent, on cognition in Idiopathic Intracranial Hypertension | Eye (London, England) | PMID 38212401 |
| 2024 | Randomised controlled trial | Trial of Lixisenatide in Early Parkinson's Disease | The New England journal of medicine | PMID 38598572 |
| 2025 | Randomised controlled trial | Skin Anti-Aging and Moisturizing Effects of Low-Molecular-Weight Collagen Peptide Supplementation in Healthy Adults: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial | Journal of microbiology and biotechnology | PMID 40935395 |
| 2024 | Randomised controlled trial | An Oral Interleukin-23-Receptor Antagonist Peptide for Plaque Psoriasis | The New England journal of medicine | PMID 38324484 |
| 2024 | Randomised controlled trial | Efficacy and Safety of Mazdutide in Chinese Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial | Diabetes care | PMID 37943529 |
| 2024 | Randomised controlled trial | Dose-response effects on HbA(1c) and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with ty | Diabetologia | PMID 38095657 |
| 2024 | Randomised controlled trial | Low-molecular-weight collagen peptides supplement promotes a healthy skin: A randomized, double-blinded, placebo-controlled study | Journal of cosmetic dermatology | PMID 37822045 |
| 2023 | Randomised controlled trial | Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: A Phase 1b, multicentre, blinded, placebo-controlled, randomized, multiple-ascending-d | Diabetes, obesity & metabolism | PMID 37264711 |
| 2026 | Randomised controlled trial | Mazdutide versus dulaglutide in Chinese adults with type 2 diabetes | Nature | PMID 41407860 |
| 2017 | Randomised controlled trial | Metabolic and immune effects of immunotherapy with proinsulin peptide in human new-onset type 1 diabetes | Science translational medicine | PMID 28794283 |
| Registration | Phase | Status | Enrolment | Title |
|---|---|---|---|---|
| NCT01664000 | PHASE1 | COMPLETED | 48 | A Safety, Pharmacokinetic and Pharmacodynamic Study of Kevetrin in Patients With Advanced Solid Tumors |
| NCT03155620 | PHASE2 | ACTIVE_NOT_RECRUITING | 1377 | Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The |
| NCT01549054 | PHASE1 | COMPLETED | 28 | A Study in Healthy Subjects to Evaluate Bioavailability of 4 Formulations of E5501 |
| NCT04259879 | NA | COMPLETED | 20 | Molecular Pathways Related to Short-term Fasting Response |
| NCT00423865 | PHASE1 | COMPLETED | 30 | Cisplatin and Everolimus in Treating Patients With Advanced Solid Tumors |
| NCT02064244 | N/A | COMPLETED | 33 | Inferior Vena Cava (IVC) Size in Acute Renal Failure |
| NCT04914845 | PHASE1 | COMPLETED | 16 | KPT-9274 in Patients With Relapsed and Refractory Acute Myeloid Leukemia |
| NCT04284774 | PHASE2 | ACTIVE_NOT_RECRUITING | 5 | Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial |
This table is retrieved from PubMed and ClinicalTrials.gov rather than assembled by hand, so it shows what is indexed — including the absences. Last retrieved 2026-09-11.
Reported dosing ranges
No human dosing has been published. The supplied evidence set does not provide P21-specific human dosing ranges, patient instructions, or a dosing schedule.
That matters because dosing cannot be safely copied across compounds. A dose used for an oral IL-23 receptor antagonist peptide, a collagen peptide supplement, or a GLP-1 receptor agonist does not become a P21 dose 1 2 3 4 5 10.
Dosing chart: evidence-supported ranges versus unsupported online claims
| Source of dosing information | P21-specific human range supported? | How to read it |
|---|---|---|
| Supplied P21-specific human studies | No | No P21-specific human dosing range is supported by the supplied evidence set. |
| Dermatology peptide trials | No | These trials studied other agents for plaque psoriasis, so their dosing cannot be treated as P21 dosing 1 2. |
| Collagen peptide trials | No | These trials studied low-molecular-weight collagen peptide products for skin outcomes, not P21 3 4. |
| GLP-1-related trials | No | These trials studied separate metabolic or neurologic agents, not P21 5 6 7 8 9 10. |
| Online claims without a cited P21 human study | No | Do not treat uncited online protocols as patient dosing guidance. |
Why no patient dosing recommendation can be made from the supplied evidence
A dosing recommendation needs more than a name and a theory. Clinicians look for human pharmacology, route of use, safety monitoring, adverse effects, patient selection, and drug interaction data. The supplied evidence set does not provide those P21-specific details.
Legal status
Our regulatory log holds no confirmed federal action for P21. That means we have not found one with a primary source — not that none exists.
This section is generated from a dated log of federal actions rather than written by hand, and it is re-checked daily against the Federal Register and FDA sources. Last checked 2026-09-11. See the full legal-status tracker for every compound we follow.
Safety
The safety profile of P21 is not established by the supplied evidence set. That is not reassurance; it means the key safety studies needed for patient decision-making are not present here.
Known adverse effects from other agents should not be pasted onto P21. For example, safety findings from trials of lixisenatide, icotrokinra, or GLP-1-related compounds apply to the studied agents and populations, not to P21 1 6 7 8 9.
Known unknowns: adverse effects, long-term safety, purity, and monitoring
- Adverse effects: the supplied evidence set does not establish P21-specific adverse effects in humans.
- Long-term safety: the supplied evidence set does not establish long-term human safety for P21.
- Contraindications: the supplied evidence set does not establish which health conditions would make P21 higher risk.
- Monitoring: the supplied evidence set does not define lab tests, symptom checks, or follow-up intervals for P21.
- Product quality: online “research use only” products may raise identity, purity, sterility, storage, and labeling concerns.
Why research-chemical products are not the same as clinician-guided treatment
A research-chemical label is not the same as clinician-guided care. It may not give a patient reliable information about sterility, identity, impurities, stability, storage, or whether the material was made for human use.
This is the safety axis we care about at Chia: licensed clinician evaluation and licensed pharmacy standards are different from no-prescription internet sourcing. When evidence is thin, product quality and clinical oversight matter even more.
Interactions
No P21 interaction studies are established in the supplied evidence set. That does not mean there are no interactions; it means the interaction risk is hard to assess from the records provided.
A clinician would still want to review prescription drugs, over-the-counter medicines, supplements, neurologic history, psychiatric history, immune conditions, pregnancy status, and major medical diagnoses. The supplied P21 evidence does not define a safe interaction profile for any of these situations.
Why interaction risk is hard to assess without human clinical data
Drug interactions are often found only after a compound has been studied in defined human groups. The retrieved trials of other agents, including GLP-1-related drugs and dermatology peptides, cannot be used to clear P21 for use with other medications 1 2 5 6 7 8 9 10.
How to obtain it legally
For P21, the practical first step is not shopping; it is a clinician conversation. Bring your goals, medication list, diagnoses, supplement list, and the exact product or claim you are considering.
Chia does not offer, prescribe, compound, or ship P21. When patients ask us about evidence-limited peptides, we focus on what is known, what is not known, what safety questions remain, and whether there are better-studied options for the goal they are trying to address.
For treatments Chia does offer, care is 100% online: a short health questionnaire is reviewed by a licensed US provider, and a prescription is written only when clinically appropriate. Medications are compounded in the US by state-licensed 503A compounding pharmacies and shipped to the patient’s door. A prescription is never guaranteed, and compounded medications are not FDA-approved.
What to bring to the visit
- Your main goal, such as cognition, recovery, metabolic health, sleep, or general aging biology.
- Your full medication list, including psychiatric, neurologic, diabetes, blood pressure, hormone, and immune medicines.
- Your supplement list, including peptides, nootropics, stimulants, sleep aids, and injectable products.
- Your diagnoses, surgeries, allergies, pregnancy plans, and any history of seizures, cancer, autoimmune disease, or severe psychiatric symptoms.
- Photos or labels of any product you are considering, especially if it is sold as “research use only.”
What a licensed provider can and cannot determine from limited evidence
A licensed provider can help you sort evidence quality, screen for obvious risks, and discuss better-studied paths. But limited P21-specific human data means a clinician may not be able to answer key questions about benefit, dose, interactions, or long-term safety from the supplied literature alone.
What a research-chemical vendor is not
A research-chemical vendor is not a medical evaluation, not a prescription, not a care plan, and not follow-up monitoring. It also does not replace a licensed pharmacy process with clear identity, sterility, purity, labeling, and storage standards.
FAQ
P21 is described as a Cerebrolysin-derived peptide discussed for preclinical neurogenesis research. The supplied evidence set does not establish human benefits for cognition, neuroprotection, longevity, or daily function.
The assigned evidence grade is A, but that grade describes the quantity and design of indexed evidence, not whether P21 works or is safe. The supplied trials are mostly not P21-specific.
No P21-specific human dosing range is supported by the supplied evidence set. Do not use online protocols as dosing instructions.
The supplied materials do not provide a verified list of companies using P21. Be careful with vendor claims that are not backed by P21-specific human evidence.
Chia does not offer, prescribe, compound, or ship P21. If you are considering any evidence-limited peptide, discuss it with a licensed clinician before trying to source it online.
The supplied materials identify P21 as the compound name and describe it as a Cerebrolysin-derived peptide. They do not provide a brand name or generic INN.
No. The supplied materials describe P21 as Cerebrolysin-derived, but that does not mean it is the same product or that evidence for Cerebrolysin applies to P21.
The supplied evidence set does not establish that P21 extends lifespan, slows aging, or improves human longevity outcomes. Longevity claims should be treated as unproven unless supported by P21-specific human data.
References
- 1.PMID 41191940 [randomised controlled trial] Bissonnette R, Soung J, Hebert AA, et al. Oral Icotrokinra for Plaque Psoriasis in Adults and Adolescents. The New England journal of medicine. 2025.
- 2.PMID 38324484 [randomised controlled trial] Bissonnette R, Pinter A, Ferris LK, et al. An Oral Interleukin-23-Receptor Antagonist Peptide for Plaque Psoriasis. The New England journal of medicine. 2024.
- 3.PMID 40935395 [randomised controlled trial] Lee E, Ahn DK, Kim JH, et al. Skin Anti-Aging and Moisturizing Effects of Low-Molecular-Weight Collagen Peptide Supplementation in Healthy Adults: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. Journal of microbiology and biotechnology. 2025.
- 4.PMID 37822045 [randomised controlled trial] Seong SH, Lee YI, Lee J, et al. Low-molecular-weight collagen peptides supplement promotes a healthy skin: A randomized, double-blinded, placebo-controlled study. Journal of cosmetic dermatology. 2024.
- 5.PMID 38212401 [randomised controlled trial] Grech O, Mitchell JL, Lyons HS, et al. Effect of glucagon like peptide-1 receptor agonist exenatide, used as an intracranial pressure lowering agent, on cognition in Idiopathic Intracranial Hypertension. Eye (London, England). 2024.
- 6.PMID 38598572 [randomised controlled trial] Meissner WG, Remy P, Giordana C, et al. Trial of Lixisenatide in Early Parkinson's Disease. The New England journal of medicine. 2024.
- 7.PMID 37943529 [randomised controlled trial] Zhang B, Cheng Z, Chen J, et al. Efficacy and Safety of Mazdutide in Chinese Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial. Diabetes care. 2024.
- 8.PMID 38095657 [randomised controlled trial] Blüher M, Rosenstock J, Hoefler J, et al. Dose-response effects on HbA(1c) and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial. Diabetologia. 2024.
- 9.PMID 41407860 [randomised controlled trial] Guo L, Zhang B, Xue X, et al. Mazdutide versus dulaglutide in Chinese adults with type 2 diabetes. Nature. 2026.
- 10.PMID 37264711 [randomised controlled trial] Pratt E, Ma X, Liu R, et al. Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: A Phase 1b, multicentre, blinded, placebo-controlled, randomized, multiple-ascending-dose study in people with type 2 diabetes. Diabetes, obesity & metabolism. 2023.
About this article
Chia Health Editorial Team — Evidence-reviewed health education
This article is for educational purposes only and is not a substitute for individualized medical advice. Talk to a licensed clinician before starting, stopping, or changing any prescription.
AI tools may assist with research and drafting. Chia's editorial team reviews source use, clarity, treatment information, and safety framing before publication. A clinician is named only after explicit sign-off. Read our editorial standards.
Get a personalized plan
See if peptide therapy is right for your body.
Our 3-minute clinical quiz is reviewed by a US-licensed clinician. Treatment delivered to your door.
